[Clostridium difficile toxin-associated diarrhea in geriatrics]

Area of Science:

• Geriatric Medicine
• Infectious Diseases
• Microbiology

Background:

• Clostridium difficile-associated diarrhea (CDAD) poses significant risks to frail elderly patients, potentially leading to pseudomembranous colitis.
• CDAD is often linked to antibiotic therapy, causing an overgrowth of Clostridium difficile in the intestinal flora.
• Symptoms of CDAD range from asymptomatic carriage to severe illness with diarrhea, abdominal pain, and fever.

Purpose of the Study:

• To report the diagnosis and treatment of Clostridium difficile-associated diarrhea in a geriatric clinic.
• To evaluate the efficacy of oral vancomycin in treating CDAD in elderly patients.
• To discuss the role of metronidazole as a potential alternative treatment.

Main Methods:

• Diagnosis involved identifying typical clinical symptoms and confirming with a toxin-positive stool specimen.
• Treatment efficacy was assessed by monitoring symptom resolution and systemic inflammatory markers.
• Literature review was conducted to compare vancomycin and metronidazole treatment guidelines.

Main Results:

• Six cases of CDAD were diagnosed and treated within a year in a geriatric clinic.
• Oral vancomycin effectively resolved diarrhea and improved inflammatory parameters in all treated patients.
• Metronidazole is suggested as the preferred agent for mild to moderate CDAD to prevent vancomycin resistance and reduce costs.

Conclusions:

• Oral vancomycin is a highly effective treatment for Clostridium difficile-associated diarrhea in elderly patients.
• Metronidazole should be considered the first-line treatment for mild to moderate CDAD to mitigate antibiotic resistance and cost concerns.
• Prompt diagnosis and appropriate treatment are crucial for managing CDAD in vulnerable geriatric populations.